The Latest Breaking News from Regeneron

The biotech industry is trying to catch the ESG investing bug. But that doesn't mean investors are giving it credit, executives say.

The biotech sector is poised to end June on a positive note, despite largely disappointing regulatory decisions scheduled during the month, thanks to a reversal in broader market sentiment.

The U.S. Food and Drug Administration (FDA) has accepted Regeneron Pharmaceuticals’ (NASDAQ: REGN) supplemental Biologics License Application (sBLA) of EYLEA (aflibercept) Injection for review in patients with diabetic retinopathy (DR).

The U.S.

The stock market gave back most of its early gains and traded near session lows in afternoon trading. Amazon.com rose in the first day of its stock split.

Regeneron stock tumbled Thursday after the company announced a deal to acquire the international rights to Sanofi-partnered cancer drug Libtayo.

With a new uptrend underway, oil stocks like TotalEnergies and tech stocks like Synopsys set the stage for new breakouts.

The U.S.

The U.S. Food and Drug Administration (FDA) has approved Regeneron Pharmaceuticals, Inc.

AbbVie could soon pressure Regeneron in eczema treatment, an analyst said Friday as Regeneron stock hit a ceiling at its 200-day line.

Regeneron Pharmaceuticals Inc (NASDAQ:REGN) earned $11.49 per share for Q1 FY22, up 16% Y/Y, beating the $10.04 estimate.  Sales increased 17% to $2.96 billion, surpassing the analysts' consensus of $2.73 billion, fueled by sales of COVID-19 treatment, REGEN-COV.  The company reported a net income of $974 million, down 13%, as its COVID-19…